SCHEMBL8053154

SCHEMBL8053154

COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1C(C)c1c[nH]c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MGAM O43451 4/20 0.45
GAA P10253 4/20 0.45
SI P14410 4/20 0.45
MGAM2 Q2M2H8 4/20 0.45
TBXA2R P21731 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9586132 0.92 GAA (0.44) MGAMGAASIMGAM2
SCHEMBL9397560 0.89 GAA (0.41) MGAMGAASIMGAM2TBXA2R
SCHEMBL8530545 0.88 ALKBH2 (0.43)
SCHEMBL8532771 0.88
SCHEMBL9395095 0.88 GAA (0.40) MGAMGAASIMGAM2
SCHEMBL14862819 0.87
SCHEMBL9397577 0.87 GAA (0.40) MGAMGAASIMGAM2
SCHEMBL9586684 0.85 MGAM (0.38) MGAMGAASIMGAM2
SCHEMBL3676853 0.81 GABRP (0.46)
SCHEMBL9472452 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6143775-A PHYSICAL FORM OF ZAFIRLUKAST; ASTHMA ZENECA LIMITED (GB) 2000-11-07 US disclosed
US-5993859-A N-(4-(5-(CYCLOPENTYLOXYCARBONYL)AMINO-1-METHYLINDOL-3-YL-METHY L)-3-METHOXY BENZOYL)-2-METHYL-BENZENESULPHONAMIDE AND POLYVINYLPYRROLIDONE. ZENECA LIMITED (GB) 1999-11-30 US disclosed
US-5612367-A Orally administering an amorphous physical form of zafirlukast in combination with polyvinylpyrrolidone ZENECA LIMITED (GB) 1997-03-18 US disclosed
EP-0490649-B1 A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it ZENECA LTD (GB) 1996-11-13 EP disclosed
US-5504216-A DEHYDRATING WITH HEATING UNDER REDUCED PRESSURE ZENECA LIMITED (GB) 1996-04-02 US disclosed
US-5482963-A Physical form of N-(4-(5(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl -methyl)3methoxybenzoyl)-2-methylbenzenesulphonamide, zafirlukast; tablet; asthma ZENECA LIMITED (GB) 1996-01-09 US disclosed
EP-0490648-B1 Pharmaceutical agents ZENECA LTD (GB) 1995-12-06 EP disclosed
US-5319097-A Physical form of leukotriene antagonist such as zafirlukast, N-(4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl)-3-methoxybenzoyl)-2methylbenzenesulfonamide; spray drying in acetone IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-06-07 US disclosed
US-5294636-A Such as zafirlukast; leukotriene antagonist; metered dose inhalers IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-03-15 US disclosed
EP-0490649-A1 A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it ZENECA LIMITED (GB) 1992-06-17 EP disclosed
EP-0490648-A1 Pharmaceutical agents ZENECA LIMITED (GB) 1992-06-17 EP disclosed